Published in final edited form as:

Lancet Infect Dis. 2010 April ; 10(4): 251–261. doi:10.1016/S1473-3099(10)70026-8.

Incidence and Lethality of Immune Reconstitution Disease in HIV-Infected Patients Starting Antiretroviral Therapy: Systematic Review and Meta-Analysis

Monika Müller¹, Simon Wandel^{1,2}, Robert Colebunders³, Suzanna Attia¹, Hansjakob Furrer⁴, and Matthias Egger^{1,5} for IeDEA Southern and Central Africa

¹International epidemiological Databases to Evaluate AIDS (IeDEA), Southern African region, Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland ²Clinical Trials Unit, Bern University Hospital, Bern, Switzerland ³IeDEA, Central African region, Institute of Tropical Medicine, Antwerp, Belgium ⁴Division of Infectious Diseases, University Hospital Bern, Switzerland ⁵Department of Social Medicine, University of Bristol, United Kingdom

Summary

This systematic review examines the incidence of Immune Reconstitution Disease (IRD) in HIV-1 infected patients starting antiretroviral combination therapy (ART). We analysed 13103 patients from 54 cohort studies; 1685 patients developed IRD. Pooled incidences with 95% credibility intervals (CrI) were calculated using Bayesian methods. In patients with previously diagnosed AIDS-defining conditions the incidence was 37.7% (95% CrI 26.6–49.4%) for CMV retinitis, 19.5% (6.7–44.8%) for cryptococcal meningitis, 15.7% (9.7–24.5%) for tuberculosis, 16.7% (2.3–50.7%) for progressive multifocal leukoencephalopathy and 6.4% (1.2–24.7%) for Kaposi's sarcoma. The incidence of any type of IRD, based on studies of unselected patients starting ART, was 16.1% (11.1–22.9%). Lethality was 4.5% (2.1–8.6%) for any type of IRD, 3.2% (0.7–9.2%) for tuberculosis and 20.8% (5.0–52.7%) for cryptococcal meningitis. Meta-regression analyses showed that the incidence is largely determined by the CD4 cell count at the start of ART, with a high risk in patients starting below 50 cells/ μ l. Many of the IRD events might therefore be prevented with earlier initiation of ART.

Introduction

Combination antiretroviral therapy (ART) substantially reduces the incidence of opportunistic events and mortality.¹ The beneficial effects of ART result from gradual

© 2010 Elsevier Ltd. All rights reserved.

Correspondence to: Professor Matthias Egger, Institute of Social and Preventive Medicine (ISPM), Finkenhubelweg 11, CH-3012 Bern, Switzerland, Tel +41 31 631 35 11, Fax +41 31 631 35 20, egger@ispm.unibe.ch.

Conflict of interest

All authors declare that they have no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

restoration of pathogen-specific immune responses, mediated by the suppression of HIV-1 replication and increases in CD4 positive T-cells (CD4 cells).²³ The World Health Organisation (WHO) estimates that about 4 million people were receiving antiretroviral therapy (ART) in low- and middle-income countries by the end of 2008, a ten-fold increase during the past five years.⁴ However, many patients in resource-poor settings start ART late, with advanced immunodeficiency.^{5,6}

Complications related to ART-induced immune reconstitution include paradoxical worsening of treated opportunistic infections or the unmasking of previously sub-clinical, untreated infections.^{7–10} This Immune Reconstitution Disease (IRD) is usually a consequence of exaggerated activation of the immune system against persisting antigen (paradoxical IRD) or viable pathogens (unmasking IRD), but may also manifest itself as progression of proliferative disease in patients with cancers.¹¹ IRD has been associated with a wide range of pathologies, including mycobacterial and cryptococcal infections, Kaposi's sarcoma, Non-Hodgkin lymphoma and progressive multifocal leukoencephalopathy (PML).^{8–10,12–14} Non-AIDS defining conditions such as sarcoidosis¹⁵ and rheumatic diseases¹⁶ may also transiently deteriorate after starting ART.

The incidence of IRD in patients initiating ART is not well defined at present, with published estimates ranging from less than 10% to over 50%.^{17–21} Several studies,^{10,14,22–24} but not all^{18,25,26} found an increased risk of IRD in patients starting ART with advanced immune deficiency. We performed a systematic review and meta-analysis of cohort studies to better define the incidence and lethality of IRD events in patients starting ART in low- and high-income countries.

Methods

Literature search and study selection

We searched the MEDLINE and EMBASE databases from January 1996 to October 2009 to identify relevant studies published in any language. We used the terms 'immune reconstitution syndrome', 'immune reconstitution disease', 'immune restitution syndrome', 'immune restitution disease', 'immune reconstitution inflammatory syndrome', and 'immune recovery uveitis'. Articles, brief reports and letters to the editors were included. Reference lists of relevant papers were screened. In addition we searched the abstracts of the International AIDS Society conferences (International AIDS conference and Conference on HIV Pathogenesis, Treatment and Prevention) and the Conference on Retroviruses and Opportunistic Infections (CROI) 2000 to 2009. We included longitudinal studies of patients starting ART. The cohort had to consist of at least ten adults starting ART and systematically record IRD events and/or the mortality of patients with IRD.

Data collection and definitions

Data on eligibility criteria, study and patient characteristics as well as IRD events (type of event, number of patients developing event, number of deaths from IRD) and duration of follow up were extracted in duplicate by two reviewers (MM and SA) using a standardized form. Disagreements were resolved by discussion with a third reviewer (ME). Common

definitions used in these studies for IRD are summarized in Table 1. We used the 2008 World Bank country classification to classify countries into high-income, higher and lower middle-income countries and low-income countries.²⁷

Statistical Analysis

We used a fully probabilistic (Bayesian) approach for meta-analysis, which is particularly suitable when there is substantial heterogeneity between the results of individual studies, by providing a flexible framework for hierarchical modelling with random effects at the study level.^{28,29} For each study the number of events was assumed to follow a binomial distribution with unknown underlying risk p . We modelled the baseline log odds of an event, i.e. $\text{logit}(p)$, as a normal random variable drawn from a common normal distribution, with the mean equal to the baseline log odds in the population of possible studies and variance representing the variability across studies. Analyses were based on non-informative prior distributions (mean 0, variance 1,000), and a uniform distribution ranging from 0 to 2 for the standard deviation of the random-effects.²⁹ Results are based on 30,000 iterations after a burn-in period of 50,000 iterations. Between-trial heterogeneity was assessed using an approximate I-squared for Bayesian meta-analysis. Further details on the Bayesian model, the choice of prior distributions and the implementation in WinBugs are provided in Webappendix 1.

We used random-effects meta-regression with inverse variance weights to examine the relationship between median CD4 cell count and incidence of IRD, and to investigate the importance of the study setting (2008 World Bank country classification²⁷) and type of publication (full article, letter, abstract). In some instances we converted median age to mean age using the method proposed by Hozo et al.³⁰ Analyses were done in WinBUGS (version 1.4.3, Cambridge, UK) and Stata (version 10.0, College Station, TX, USA). Data are presented as percentage of patients developing IRD events, with 95% credibility intervals (CrI) for combined estimates from meta-analysis, and 95% confidence intervals (CI) for study-specific estimates, and as coefficients from meta-regression models, which can be interpreted as risk ratios.

Results

The search identified 856 reports and 118 abstracts. 54 eligible cohort studies were identified: 22 (41%) were published as full articles, 21 (39%) as abstracts and eleven (20%) as letters to the editor. Figure 1 illustrates the process of identifying eligible studies and gives reasons for exclusions.

Table 2 summarises study and patient characteristics. The 54 studies were from 23 different countries. Seventeen cohorts (31%) were in unselected patient groups that included patients with and without AIDS and studied any type of IRD.^{22,23,26,31–38} The remaining studies were in patients with previously diagnosed conditions and examined their paradoxical worsening after starting ART: tuberculosis (16 studies, 30%),^{18,19,24,25,39–47} cryptococcal meningitis (6 studies, 11%),^{12,20,48–50} cytomegalovirus (CMV) retinitis (10 studies, 19%),^{21,51–58} herpes zoster (1 study, 2%),⁵⁹ Kaposi's sarcoma (2 studies, 4%)^{17,60} and progressive multifocal leucoencephalopathy (2 studies, 4%). Twenty studies (37%) used one of the definitions listed

in Table 1, fourteen (26%) used another definition and in twenty studies (37%) the definition was unclear.

The cohorts included a median of 75 patients (range 10 to 2330 patients), the total number was 13103 patients. Length of follow up was reported in 17 studies: the median was 12 months (range 5 to 37 months). Nineteen studies (35%) were from high-income countries (Australia, France, Ireland, Japan, South Korea, Spain, United Kingdom, Germany, Taiwan and USA), 17 (31%) from higher middle-income countries (Argentina, Brazil, Mexico, Poland, Serbia, South Africa and Venezuela), another 15 (28%) from lower middle-income countries (India and Thailand) and three (6%) from low-income countries (Cambodia, Mozambique and Senegal). 19 cohorts (35%) were from the Asia-Pacific region, thirteen (24%) from Europe, seven (13%) from North America, six (11%) from South America and nine (17%) from Africa. Mean age was available for 21 studies (39%): the median across studies was 36.3 years (range 34 to 41 years). The CD4 count at the start of ART was reported in 22 studies (41%): the median across studies was 57 cells/ μ l (range 17 to 174 cells/ μ l).

A total of 1685 patients developed IRD. Figure 2 shows the meta-analysis of the incidence of IRD events in patients with previously diagnosed opportunistic illnesses and of any type of IRD, based on studies of unselected patients starting ART. The incidence of IRD ranged from 6.4% (95% CrI 1.2–24.7%) among patients with Kaposi sarcoma, based on two studies, to 37.7% (26.6–49.4%) among patients with CMV retinitis (10 studies); with the incidence of IRD associated with tuberculosis (16 studies), cryptococcal meningitis (6 studies), herpes zoster (one study) and progressive multifocal leucoencephalopathy (2 studies) in intermediate positions. The incidence of any type of IRD, based on 17 studies of unselected patients starting ART, was 16.1% (11.1–22.9%). The degree of between-study heterogeneity ranged from moderate to high: approximate I-squared values were 45% for Kaposi sarcoma, 63.7% for immune recovery uveitis, 93.1% for tuberculosis, 93.7% for cryptococcal meningitis, 97.1% for progressive multifocal leucoencephalopathy and 97.1% for any IRD (Figure 2).

The meta-regression analysis of the relationship between median CD4 counts at the start of ART and the incidence of IRD, based on 22 studies with available CD4 count data, is shown in Figure 3: there was an exponential increase in the incidence as the median CD4 count declined, independently of the pathology studied. As expected, in meta-regression models including both baseline CD4 counts and pathology, the coefficients associated with the different pathologies were attenuated whereas little change was seen in the coefficient for baseline CD4 count.

In stratified analyses, the incidence of tuberculosis-associated IRD was 20.7% (95% CrI 9.0–45.7%), based on four studies²⁴⁴²⁴⁴ in patients starting ART with fewer than 50 cells/ μ l, compared to 17.7% (5.4–54.2%) in patients starting above this threshold (based on four studies¹⁸²⁵³⁹⁴¹). The difference was more extreme for cryptococcal meningitis: incidences were 28.3% (6.1–68.2%) and 2.0% (0.2–15.5%), based on two⁴⁸⁵⁰ and one study,²⁰ respectively. All four studies²¹⁵²⁵³ of CMV retinitis with information on CD4 cell counts at baseline reported median counts below 50 cells/ μ l; the combined incidence was 37.7%

(16.8–61.7%). Six studies reported a CD4 cell count for any type of IRD. All of them started with median counts above 50 cells/μl: the combined incidence was 17.7% (10.5–27.7%).

Finally, in a model including pathology and 2008 World Bank country classification, the risk of IRD decreased when moving from high-income to higher middle-income, lower middle-income and low-income country. The risk ratio per change in category was 0.76 (95% CI 0.59 to 0.97, $p = 0.03$). In stratified analyses the incidence of tuberculosis was 21.3% (95% CrI 8.9–43.0), based on eight studies in high-income countries, 13.9% (6.0–26.4%) based on three studies from higher middle-income countries, 9.4% (3.8–22.0%) based on four studies in lower middle-income countries and 22.2% (8.6–42.3%) based on one study from a low-income country. The corresponding incidences for cryptococcal meningitis were 36.0% (10.2–77.1%), based on two studies from high-income countries, 12.1% (2.2–45.2%) based on three studies from higher middle-income countries and 19.2% (9.6–32.5%) based on one study from a lower middle-income country. There were no studies of cryptococcal meningitis or CMV retinitis from low-income countries. There was little evidence of a trend in the incidence of immune recovery uveitis: 35.9% (9.6–72.9%) in four studies from high-income countries, 41.4% (23.1–60.0%) in four studies from higher middle-income countries and 32.4% (13.4–62.6%) in two studies from lower middle-income countries. In the same model there was little evidence for an association of publication type and incidence of IRD ($p=0.40$).

Information on deaths in patients developing IRD was available from 23 cohorts (Table 2). A total of 52 deaths were explicitly attributed to IRD. Lethality was 4.5% (95% CrI 2.1–8.6%) for any type of IRD, 3.2% (0.7–9.2%) for tuberculosis-associated IRD and 20.8% (5.0–52.7%) for IRD related to cryptococcal meningitis. Eleven cohorts reported both the total number of deaths and the number of deaths due to IRD: 33 (20.9%) of 158 deaths were attributed to IRD, including three studies reporting zero deaths. The proportion of deaths attributed to IRD was similar when restricting the latter analysis to the four studies of any type of IRD: 17 (21.8%) of 78 deaths were attributed to IRD.

Discussion

This systematic review and meta-analysis of cohort studies in patients starting ART showed that the incidence of IRD varies across groups of patients with different AIDS-defining events. The incidence was highest in patients with CMV retinitis and also high in patients with cryptococcal meningitis and tuberculosis, but less common in Kaposi's sarcoma or herpes zoster. Interestingly, differences in the incidence of IRD between pathologies appeared to be explained by different CD4 cell counts at baseline. Based on the studies in unselected patients with and without a history of AIDS, which examined any type of IRD event, about every sixth patient developed the syndrome, but the results from these studies were highly heterogeneous. The lethality of patients developing IRD overall was about 4%, but much higher for IRD associated with cryptococcal meningitis.

Our study was based on a comprehensive literature search and included data that were presented at conferences but not published, thus reducing possible publication bias. We identified 54 cohort studies in over 13000 patients from 23 different countries, including

high-, middle- and low-income countries. We included both studies in patients with diagnosed pathologies, which focussed on paradoxical reactions to ART, and studies of unselected patient groups, which assessed any type of IRD, including the unmasking of sub-clinical infections.⁶¹ The synthesis of these studies represents the best available evidence on the incidence of IRD following the initiation of ART, but we acknowledge that meta-analyses of observational studies are prone to the biases inherent in the original studies.⁶² Our review was exclusively based on aggregated data, and important information, including, for example, on the CD4 count at the start of ART or the duration of follow up, was often missing. This was not surprising considering that many of the studies were available as conference abstracts only. It also meant that in-depth assessments of study quality were not possible.

There was substantial heterogeneity in the results from the different studies, particularly between studies of unselected patients groups, but also for some of the studies of patients with AIDS. Several factors may have contributed to between-study heterogeneity. Firstly, there is little agreement on the diagnostic criteria for IRD, although criteria for the diagnosis of tuberculosis-associated IRD have recently been developed by the International Network for the Study of HIV-associated IRD.⁶¹ Particularly the unmasking type of IRD is difficult to diagnose: differentiating between an opportunistic infection with normal presentation and an infection with a presentation compatible with unmasking IRD is not straightforward.⁶³ In paradoxical IRD alternative explanations for the deterioration, including, for example, the failure of the treatment of the opportunistic infection or the failure of ART due to lack of adherence or drug resistance must be excluded. Differences in the diagnostic criteria used in the different studies may thus well have introduced heterogeneity. There is likely to be a continuum from intended ART-associated immune reconstitution to the undesired manifestations of IRD, and even with clearly defined criteria there will be some room for subjective interpretation.

Studies that planned data collection in advance will probably achieve more complete ascertainment of cases and more consistent diagnoses compared to studies based on retrospective chart review. While this was often unclear from the published reports, the nature of the study and data collection will have been another source of heterogeneity. The more limited diagnostic capacity might have rendered case ascertainment less complete in resource-constrained settings. Indeed, we found that the incidence of IRD tended to be lower in cohorts from middle- and low-income countries, compared to high-income countries. This result was mainly driven by IRD associated with tuberculosis and cryptococcal meningitis, whereas no such trend was observed for immune recovery uveitis. This is not surprising: inflammatory reactions, even if moderate, are more likely to be recognised in the eye than in other organs.

The CD4 cell count at the start of ART is another source of heterogeneity. We could examine the relationship between the incidence of IRD and the median CD4 cell count at the start of ART in 22 studies. The results from the meta-regression model showed that low CD4 counts at the start of ART drive the incidence of IRD, independently of the pathology involved. Indeed, we found a high incidence of IRD events in patients starting ART below 50 cells/ μ l, including events associated with tuberculosis, CMV-associated immune

recovery uveitis and cryptococcal meningitis. The high incidence of IRD in patients with CMV retinitis is not surprising: this diagnosis is typically made when the CD4 count has dropped below 50 cells/ μ L.^{64,65} Cryptococcal meningitis also tends to occur at low CD4 counts, whereas Kaposi's sarcoma and tuberculosis also occur at higher counts.⁶⁵

Our review did not cover all AIDS-defining events. For example, we failed to identify an eligible study of IRD in patients with *Pneumocystis jirovecii* pneumonia. A recent randomised clinical trial in patients with acute opportunistic infections, which compared immediate ART with ART given after treatment of the acute infection, found that 7.3% of 177 patients with *Pneumocystis jirovecii* pneumonia developed IRD.⁶⁶ This incidence was low considering the median CD4 cell count of 29 cells/ μ L. The low incidence of IRD in this trial might be related to the patient inclusion criteria, the use of corticosteroids, or to chance: the 95% confidence interval was wide (4.0%–12.2%). We cannot, however, exclude that the risk of IRIS may be lower for some opportunistic infections, independently of the CD4 count.

We found that 21% of all deaths had been attributed to IRD, with lethality ranging from about 3% in patients with tuberculosis-associated IRD to over 20% in patients with cryptococcal meningitis. In contrast, a recent study from Uganda reported that only four (5.8%) out of 69 HIV-related deaths in the first year of ART were due to IRD.⁶⁷ Our review may thus have overestimated the contribution of IRD to early mortality. Although we included deaths that were explicitly attributed to IRD only, attribution may have been inaccurate: other AIDS-defining conditions and drug toxicity may have played a role in some of these deaths. We included the studies that reported zero deaths in patients with IRD, but selective reporting of data on mortality in studies where such deaths occurred may also have played a role. Alternatively, the Ugandan study, which did not systematically assess all IRD events and determined causes of death based on retrospective chart review and verbal autopsy, may have under ascertained IRD-related deaths. As Davies and Meintjes pointed out in their commentary, the relative importance of different opportunistic infections, the degree of access to facilities for their diagnosis and the extent of screening for and treatment of opportunistic infections before ART initiation will influence the incidence of IRD events and their contribution to mortality in a given setting.⁶³

The immunopathological process underlying IRD is not fully understood at present, but data from clinico-pathological and immunological studies indicate that IRD results from exaggerated and dysregulated cellular immune responses that depend on the pathogen involved.¹¹⁶⁸ If the provoking pathogen is viral, for example *Cytomegalovirus*, CD8 positive T-lymphocytes predominate in inflammatory cell infiltrates whereas granulomatous CD4 T helper cell type 1 (Th1) inflammation predominates if the pathogen is mycobacterial, for example *M. tuberculosis*, or a fungus, for example *Cryptococcus neoformans*.¹¹⁶⁸ A recent study showed that expansion of *M. tuberculosis* antigen-specific T-cells also occurred in the majority of patients not developing IRD, suggesting that other factors are involved.⁶⁹ Regulatory T cells may not expand at the same rate as the antigen-specific effector cells, resulting in dysregulated immune activation and a “cytokine storm”.^{70,71} A comparative study in patients with HIV and tuberculosis recently showed similar expansion of regulatory T cells but reduced functional capacity in patients with IRD.⁷² Finally, little is known about

how best to treat IRD although corticosteroid therapy appears to be efficacious in severe cases.¹¹⁶³

In conclusion, IRD is a common complication in patients starting ART. It is particularly common in patients with a history of CMV retinitis, cryptococcal meningitis and tuberculosis, and in patients who start ART at low CD4 cell counts. It is probably under diagnosed in resource-limited settings, and may contribute to the high early mortality in these settings.²⁰⁷³ As was done for IRD associated with tuberculosis⁶¹ it is important that international consensus case definitions for IRD are developed for other AIDS-defining events. Authors reporting on IRD should always state which definitions were used, and whether data collection was prospectively planned or based on retrospective chart reviews. Further research is needed to better understand the immunopathogenesis of the various types of IRD, so that diagnostic tests and effective therapies can be developed. Finally, although our study cannot determine the CD4 cell count when ART should best be started, our results indicate that many IRD events and much of the excess mortality that is observed in the first few months ART in resource-limited settings might be preventable with timely initiation of ART, before patients are at risk for developing opportunistic infections.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Olivia Keiser, Andri Rauch, Mar Pujades-Rodriguez and three anonymous referees for helpful comments on an earlier draft of this paper.

References

1. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. *Lancet*. 2005; 366(9483):378–84. [PubMed: 16054937]
2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. *Science*. 1997; 277(5322):112–6. [PubMed: 9204894]
3. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. *Lancet Infect Dis*. 2006; 6(5):280–7. [PubMed: 16631548]
4. Organization WH. 2009 Progress Report. Geneva: World Health Organization; 2009. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector.
5. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boule A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet*. 2006; 367(9513):817–24. [PubMed: 16530575]
6. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boule A, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. *Trop Med Int Health*. 2008; 13(7):870–9. [PubMed: 18373510]
7. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. *Lancet Infect Dis*. 2007; 7(6):395–401. [PubMed: 17521592]
8. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. *Lancet Infect Dis*. 2005; 5(6):361–73. [PubMed: 15919622]

9. Shelburne ISA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, et al. Immune reconstitution inflammatory syndrome: Emergence of a unique syndrome during highly active antiretroviral therapy. *Medicine*. 2002; 81(3):213–227. [PubMed: 11997718]
10. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. *AIDS*. 2004; 18(12):1615–1627. [PubMed: 15280772]
11. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. *Clin Infect Dis*. 2009; 48(1):101–7. [PubMed: 19025493]
12. Shelburne ISA, Darcourt J, White AC Jr, Greenberg SB, Hamill RJ, Atmar RL, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related *Cryptococcus neoformans* disease in the era of highly active antiretroviral therapy. *Clin Inf Dis*. 2005; 40(7):1049–1052.
13. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. *Annals of Internal Medicine*. 2000; 133(6):447–454. [PubMed: 10975963]
14. Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. *Int J Tuberc Lung Dis*. 2006; 10(9):946–53. [PubMed: 16964782]
15. Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. *Clin Inf Dis*. 2003; 36(8):1047–1052.
16. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. *Semin Arthritis Rheum*. 2005; 35(3):166–74. [PubMed: 16325657]
17. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. *J Clin Oncol*. 2005; 23(22):5224–8. [PubMed: 16051964]
18. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, Balakrishnan P, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. *J Acquir Immune Defic Syndr*. 2004; 37(5):1574–6. [PubMed: 15577411]
19. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. *American Journal of Respiratory and Critical Care Medicine*. 1998; 158(1):157–161. [PubMed: 9655723]
20. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. *AIDS*. 2005; 19(17):2050–2. [PubMed: 16260920]
21. Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. *AIDS*. 2005; 19(7):735–8. [PubMed: 15821403]
22. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. *HIV Medicine*. 2000; 1(2):107–15. [PubMed: 11737333]
23. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. The prevalence and risk immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. *HIV Medicine*. 2005; 6(2):140–143. [PubMed: 15807721]
24. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. *AIDS*. 2006; 20(2):F1–F7. [PubMed: 16511406]
25. Breton G, Duval X, Estellat C, Poalletti X, Bonnet D, Mvondo Mvondo D, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. *Clin Inf Dis*. 2004; 39(11):1709–12.
26. Pulimood, SA.; Chandrasekharan, J.; Kannangai, R. Incidence of immune reconstitution inflammatory syndrome (IRIS) in a cohort of HIV-infected patients on highly active antiretroviral

- therapy (HAART) from South India. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney. 22–25 July 2007; p. Abstract WEPEB071
27. United Nations. Human Development Report. New York: United Nations; 2008.
 28. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. *J Am Coll Cardiol.* 2008; 51(1):37–45. [PubMed: 18174034]
 29. Spiegelhalter, D.; Abrams, K.; Myer, J. Bayesian Approaches to Clinical Trials and Health-Care Evaluations. Hoboken, NJ: Wiley; 2004.
 30. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol.* 2005; 5(1):13. [PubMed: 15840177]
 31. Bhrushundi, M.; Mishra, P. Study of immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. XVI International AIDS Conference; Toronto. 13–18 August, 2006; p. Abstract MOAB0305
 32. Chenghat, V.; Parthasarathy, M.; Athappan, G. Adverse drug reactions in patients receiving antiretroviral therapy – a prospective study. 8th International Congress on Drug Therapy in HIV Infection; Glasgow. November 12–16, 2006; p. Abstract 44
 33. Rajasekaran S, Vijila, Ravichandran N. Immune Reconstitution tuberculosis in HIV patients after antiretroviral therapy. *JK Science.* 2006; 8(4):205–207.
 34. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. *Clin Inf Dis.* 2006; 42(3):418–27.
 35. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. *AIDS.* 2005; 19(4):399–406. [PubMed: 15750393]
 36. Thomas, MS. HAART and PLWHAS from an urban low socio economic community. XV International AIDS Conference; Bangkok. 11–16 July 2004; p. Abstract TuPeB4514
 37. Wijayasangary, K.; Arunachalam, C.; Tharmasangary, W. Immune reconstitution syndrome observed in resource poor clinical settings in south India. XVI International AIDS Conference; Toronto. 13–18 August, 2006; p. Abstract THPE0083
 38. Wnuk, A.; Pynka, M.; Boro -Kaczmarska, A. Immune restoration disease (IRD) during the first 6 months after HAART. 2nd IAS Conference on HIV Pathogenesis, Treatment and Prevention; Paris. July 13–17, 2003; p. Abstract 428
 39. Chew, NS.; Brannigan, E.; Nugent, C.; Lambert, J. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy in a north Dublin inner city hospital. 8th International Congress on Drug Therapy in HIV Infection; Glasgow. November 12–16, 2006; p. Abstract 279
 40. Elliott, JH.; Sarun, S.; Mean, CV. Tuberculosis-associated immune restoration disease is associated with increased PPD-specific T cell responses detected by a whole blood interferon- γ release assay. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney. 22–25 July 2007; p. Abstract MOAB101
 41. Lawn SD, Myer L, Bekker LG, Wood R, Lawn SD, Myer L, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. *AIDS.* 2007; 21(3):335–41. [PubMed: 17255740]
 42. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. *Journal of Infection.* 2006; 53(6):357–63. [PubMed: 16487593]
 43. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. *Antiviral Therapy.* 2005; 10(3):417–22. [PubMed: 15918332]
 44. Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortun J, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. *Archives of Internal Medicine.* 2002; 162(1):97–9. [PubMed: 11784229]

45. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, et al. Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. *AIDS*. 2007; 21(7):875–7. [PubMed: 17415046]
46. Serra FC, Hadad D, Orofino RL, Marinho F, Lourenco C, Morgado M, et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. *Braz J Infect Dis*. 2007; 11(5):462–5. [PubMed: 17962870]
47. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. *Chest*. 2001; 120(1):193–7. [PubMed: 11451837]
48. Jenkin, L.; Karstaedt, A. Cryptococcal complications in the first year on HAART: experiences of a South African antiretroviral programme. XVI International AIDS Conference; Toronto. 13–18 August, 2006; p. Abstract THPE0080
49. Jenny-Avital ER, Abadi M, Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. *Clin Inf Dis*. 2002; 35(12):e128–33.
50. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2007; 45(5):595–6.
51. Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. *Retina*. 2003; 23(4):495–502. [PubMed: 12972761]
52. Banker AS, Patel A. Effect of combination antiretroviral therapy on cytomegalovirus retinitis. *Indian J Ophthalmol*. 2002; 50(1):29–33. [PubMed: 12090084]
53. Colombero, D.; Agostini, M.; Lupo, S. Immune recovery uveitis in the HAART era. XV International AIDS Conference; Bangkok. 11–16 July 2004; p. Abstract WePeB5919
54. Dujic M, Jevtovic D. Immune recovery vitritis. *Srp Arh Celok Lek*. 2007; 135(9–10):513–5. [PubMed: 18088034]
55. Karavellas MP, Azen SP, MacDonald JC, Shufelt CL, Lowder CY, Plummer DJ, et al. Immune recovery vitritis and uveitis in AIDS: Clinical predictors, sequelae, and treatment outcomes. *Retina*. 2001; 21(1):1–9. [PubMed: 11217922]
56. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. *American Journal of Ophthalmology*. 2000; 129(5):634–639. [PubMed: 10844056]
57. Sarkar, K.; Guha, S.; Bandopadhyay, M. Immune recovery uveitis in acquired immunodeficiency syndrome: incidence, spectrum, clinical predictors in a defined Indian population. XVI International AIDS Conference; Toronto. 13–18 August, 2006; p. Abstract THPE0078
58. Uemura A, Yashiro S, Takeda N, Oka S. Ocular complications in patients with human immunodeficiency virus infection. *Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc)*. 2006; 110(9):698–702.
59. Dunic I, Djurkovic-Djakovic O, Vesic S, Zerjav S, Jevtovic D. Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors. *International Journal of STD and AIDS*. 2005; 16(7):475–478. [PubMed: 16004625]
60. De Schacht, C.; Samura, FS.; Lynen, L. Treatment of Kaposi's sarcoma in a resource poor setting: experience in Tete, Mozambique. 3rd IAS Conference on HIV Pathogenesis and Treatment; Rio de Janeiro. 24–27 July, 2005; p. Abstract TuPe7.7C12
61. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis*. 2008; 8(8):516–23. [PubMed: 18652998]
62. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies *BMJ*. 1998; 316(7125):140–4.
63. Davies MA, Meintjes G. Assessing the contribution of the immune reconstitution inflammatory syndrome to mortality in developing country antiretroviral therapy programs. *Clin Infect Dis*. 2009; 49(6):973–5. [PubMed: 19673616]

64. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. *J Acquir Immune Defic Syndr*. 1991; 4(8):770–6. [PubMed: 1677419]
65. Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, Johnson MA, et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. *Archives of Internal Medicine*. 1998; 158(5):491–7. [PubMed: 9508227]
66. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. *PLoS One*. 2009; 4(5):e5575. [PubMed: 19440326]
67. Castelnovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. *Clin Infect Dis*. 2009; 49(6): 965–72. [PubMed: 19673615]
68. Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. *Curr Opin HIV AIDS*. 2008; 3(4):419–24. [PubMed: 19373000]
69. Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. *Am J Respir Crit Care Med*. 2008; 178(10):1083–9. [PubMed: 18755923]
70. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. *AIDS*. 2006; 20(2):F1–7. [PubMed: 16511406]
71. Ruhwald M, Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? *AIDS*. 2007; 21(7):882–4. [PubMed: 17415049]
72. Seddiki N, Sasson SC, Santner-Nanan B, Munier M, van Bockel D, Ip S, et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. *Eur J Immunol*. 2009; 39(2):391–403. [PubMed: 19180462]
73. Eshun-Wilson, I.; Havers, F.; Nachega, J.; Prozesky, H.; Taljaard, J.; Zeier, M., et al. Evaluating TB-associated Immune Reconstitution Inflammatory Syndrome Using Standardized Case Definitions. 16th Conference on Retroviruses and Opportunistic Infections; Montréal. February 8–11, 2009; p. Abstract 768
74. Kumarasamy, N.; Venkatesh, K.; Vignesh, V.; Devaleenol, B.; Poongulali, S.; Yephthomi, T., et al. Immunologic outcome following HAART among HIV-infected patients developing immune reconstitution inflammatory syndrome of tuberculosis in South India. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town. 19–22 July 2009; p. Abstract TUPEB161
75. Manosuthi, W.; Van Tieu, H.; Mankatitham, W.; Lueangniyomkul, A.; Ananworanich, J.; Avihingsanon, A., et al. Clinical case definition and manifestations of paradoxical tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town. 19–22 July 2009; p. Abstract TUPEB158
76. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. *J Acquir Immune Defic Syndr*. 2009; 51(2):130–4. [PubMed: 19365271]
77. Lin YC, Yang CH, Lin CP, Yang CM, Chen MS, Chen MY, et al. Cytomegalovirus retinitis and immune recovery uveitis in AIDS patients treated with highly active antiretroviral therapy in Taiwanese. *Ocul Immunol Inflamm*. 2008; 16(3):83–7. [PubMed: 18569793]
78. Vidal JE, Penalva de Oliveira AC, Fink MC, Pannuti CS, Trujillo JR. AIDS-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in Sao Paulo, Brazil. *Rev Inst Med Trop Sao Paulo*. 2008; 50(4):209–12. [PubMed: 18813759]
79. Corral, I.; Casado, JL.; Garcia, J.; Moreno, A.; Dronda, F.; Quereda, C., et al. Progressive multifocal leukoencephalopathy (PML) in AIDS patients receiving potent antiretroviral therapies: changes in clinical presentation, diagnosis, and prognosis. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town. 19–22 July 2009; p. Abstract WEPEB204

80. Rathinam SR, Usha KR, Rao NA, Rathinam SR, Usha KR, Rao NA. Presumed trematode-induced granulomatous anterior uveitis: a newly recognized cause of intraocular inflammation in children from south India. *American Journal of Ophthalmology*. 2002; 133(6):773–9. [PubMed: 12036668]
81. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. *AIDS*. 2008; 22(5):601–10. [PubMed: 18317001]
82. Sharma A, Makrandi S, Modi M, Marfatia Y. Immune reconstitution inflammatory syndrome. *Indian J Dermatol Venereol Leprol*. 2008; 74(6):619–21. [PubMed: 19171986]
83. Haddow, L.; Moosa, Y.; Moodley, P.; Parboosing, R.; Mosam, A.; Khanyile, N., et al. Using TB Screening and Pre-ART Serology to Predict Immune Reconstitution Inflammatory Syndrome in a Resource-limited Setting with High TB and HIV Prevalence. 16th Conference on Retroviruses and Opportunistic Infections; Montréal. February 8–11, 2009; p. Abstract 767
84. Hoyo-Ulloa, I.; Galindo-Fraga, A.; Crabtree-Ramírez, B.; Pérez-Aguinaga, ME.; Sierra-Madero, J. Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and hospitalization in HIV-infected patients who started HAART in Mexico. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town. 19–22 July 2009; p. Abstract WEPED206
85. Khaykin, P.; Brodt, HR.; Staszewski, S.; Bickel, M.; Helm, E-B.; Klauke, S., et al. Risk and incidence of immune reconstitution inflammatory syndrome following initial highly active antiretroviral therapy. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town. 19–22 July 2009; p. Abstract TUPEB156
86. Poda GE, Seydi M, Manga NM, Dieng AB, Sow PS. Immune reconstitution syndrome in the course of antiretroviral treatment in Senegal. *Med Mal Infect*. 2009; 39(5):350–1. [PubMed: 19282119]

Box 1**Search strategy and selection criteria**

These are described in detail in the Methods section on page xxx.

Figure 1. Identification of eligible cohort studies of HIV-infected patients starting antiretroviral therapy.

Figure 2. Meta-analysis of 54 cohort studies of the incidence of immune reconstitution disease (IRD) in HIV-infected patients starting antiretroviral therapy

Estimates of incidences in percent from individual studies with 95% confidence intervals (95% CI) and combined estimates with 95% credibility intervals (95% CrI) are shown.

Figure 3. Incidence of immune reconstitution disease (IRD) in 22 cohort studies according to median CD4 count at the start of antiretroviral therapy

The solid line shows the predicted percentage from the meta-regression model, the dotted lines indicate the 95% confidence intervals. The size of circles is proportional to the weight in the random-effect model.

Table 1**Commonly used definitions of the Immune Reconstitution Inflammatory Syndrome****1) French¹⁰**

Diagnosis requires both major criteria or one major criterion plus two minor criteria:

Major criteria

- 1** Atypical presentation of opportunistic infections or tumours in patients responding to ART
 - Exaggerated and atypical inflammatory reaction
 - Progressive organ dysfunction or enlargement of pre-existing lesions after definite clinical improvement with pathogen-specific therapy before the initiation of ART
 - Exclusion of alternative causes (drug toxicity, newly acquired infection or tumor, treatment failure)
- 2** Decrease in plasma HIV RNA level by >1log copies/ml

Minor criteria

- 1** Increased blood CD4-count after ART
- 2** Increase in an immune response specific to the relevant pathogen, e.g. DTH response to mycobacterial antigens
- 3** spontaneous resolution of disease without specific antimicrobial therapy or tumor chemotherapy with continuation of ART

2) Shelburne⁹

Criteria for diagnosis of any IRIS case include the following four criteria:

- 1** HIV-infected patient
- 2** Receiving effective ART as evidenced by a decrease in HIV RNA concentration from baseline or increase in CD4 cells from baseline
- 3** Clinical symptoms consistent with inflammatory process
- 4** Clinical course not consistent with
 - expected course of previously diagnosed opportunistic infection
 - expected course of newly diagnosed opportunistic
 - drug toxicity

Additional criteria for cryptococcal meningitis:

- 1** Decrease of CSF antigen
- 2** Negative CSF fungal cultures
- 3** Inflammatory reaction in CSF (increased WBC count)

3) International Network for the Study of HIV-associated IRIS (INSHI)⁶¹

Case definition for TB-associated IRIS in resource-limited settings

- A.** Antecedents
 - TB-diagnosis according to WHO guidelines before starting ART
 - TB should have stabilized or improved before starting ART
- B.** Clinical criteria
 - New enlarging lymph nodes, cold abscesses or other focal tissue involvement
 - New or worsening radiological features of TB
 - New or worsening CNS tuberculosis
 - New or worsening serositis
- C.** Exclusion of alternative causes

Failure of TB treatment (non-compliance or resistance)

Other opportunistic infection or neoplasm

Drug toxicity reaction

4) Wendel⁴⁷

Paradoxical worsening of Tuberculosis is defined as:

- 1 Documented worsening of signs or symptoms of TB (fever, cough, adenopathy) or exacerbation of disease at other extrapulmonary sites during appropriate treatment
 - 2 Worsening of pulmonary infiltrates on chest radiograph or CT without other etiology
-

5) Karavellas⁵⁵

Immune reconstitution uveitis is defined as:

- 1 Patients with symptomatic onset of vitreous inflammation in the setting of inactive CMV retinitis, i.e.:
 - vitritis of 1+ or greater severity
 - significant floaters and/or decrease in vision of one or more lines
 - 2 With or without papillitis or macula changes
-

Table 2

Characteristics of 54 cohort studies of Immune Reconstitution Disease in HIV-infected patients starting antiretroviral therapy.

Author (Year)	Percent with AIDS at enrolment	Definition of IRIS *	Type of publication	Country	Study period	Mean age (years)	Median CD4 cell count (cells/ μ l)	No. of patients	No. developing IRIS	No. of deaths from IRIS
Tuberculosis (pulmonary and extrapulmonary)										
Narita (1998) ¹⁹	100%	4	Article	USA	1996–1997	n.r.	n.r.	33	12	n.r.
Wendel (2001) ¹⁷	100%	4	Article	USA	1996–2000	n.r.	n.r.	24	3	n.r.
Navas (2002) ⁴⁴	100%	Other	Letter	Spain	1995–1998	36.3	35	17	6	0
Breton (2004) ²⁵	100%	2	Letter	France	1996–2001	35.0	100	37	16	n.r.
Kumarasamy (2004) ¹⁸	100%	Other	Letter	India	2000–2003	34.0	122	144	11	n.r.
Michailidis (2005) ⁴³	100%	Other	Article	United Kingdom	2001–2003	37.4	n.r.	55	14	n.r.
Bourgarit (2006) ²⁴	100%	1	Article	France	n.r.	39.1	32	19	7	n.r.
Chew (2006) ³⁹	100%	n.r.	Abstract	Ireland	2004–2006	n.r.	82	16	4	0
Manosuthi (2006) ⁴²	100%	1	Article	Thailand	2003–2004	34.5	36	167	21	2
Elliott (2007) ⁴⁰	100%	n.r.	Abstract	Cambodia	n.r.	n.r.	n.r.	27	6	1
Lawn (2007) ⁴¹	100%	Other	Article	South Africa	2002–2005	n.r.	68	160	19	2
Park (2007) ⁴⁵	n.r.	2	Letter	South Korea	1998–2005	38.0	n.r.	482	9	n.r.
Serra (2007) ⁴⁶	100%	4	Article	Brasil	2000–2003	n.r.	n.r.	84	10	0
Eshun-Wilson (2009) ⁷³	100%	3	Abstract	South Africa	2003–2008	n.r.	n.r.	337	56	6
Kumarasamy (2009) ⁷⁴	100%	1	Abstract	India	1996–2008	n.r.	n.r.	1731	95	0
Manosuthi (2009) ⁷⁵	100%	3	Abstract	Thailand	2006–2007	35	43	126	21	0
Cryptococcal meningitis										
Jenny-Avital (2002) ⁴⁹	100%	n.r.	Article	USA	1998–2001	n.r.	n.r.	10	5	n.r.
Lawn (2005) ²⁰	95%	n.r.	Letter	South Africa	2002–2005	34.0	86	434	9	6
Shelburne (2005) ¹²	n.r.	2	Letter	USA	n.r.	n.r.	n.r.	59	18	1
Jenkin (2006) ⁴⁸	100%	2	Abstract	South Africa	2004–2005	n.r.	32.5	59	23	9

Author (Year)	Percent with AIDS at enrolment	Definition of IRIS *	Type of publication	Country	Study period	Mean age (years)	Median CD4 cell count (cells/ μ l)	No. of patients	No. developing IRIS	No. of deaths from IRIS
Sungkanupharph (2007) ⁵⁰	100%	1	Letter	Thailand	n.r.	34.4	26	52	10	0
Bicanic (2009) ⁷⁶	100%	Other	Article	South Africa	2005–2006	n.r.	n.r.	65	11	3
Immune recovery uveitis										
Nguyen (2000) ⁵⁶	100%	Other	Article	USA	1995–1998	n.r.	n.r.	33	6	n.r.
Karavellas (2001) ⁵⁵	100%	5	Article	USA	1996–1998	n.r.	n.r.	30	19	n.r.
Banker (2002) ⁵²	100%	5	Article	India	1998–2000	37.3	36.5	12	5	n.r.
Arevalo (2003) ⁵¹	100%	5	Article	Venezuela	1998–2000	n.r.	n.r.	32	12	n.r.
Colombero (2004) ⁵³	100%	1	Abstract	Argentina	n.r.	n.r.	32	30	9	n.r.
Ortega-Larrocea (2005) ²¹	100%	Other	Letter	Mexico	1996–2003	n.r.	19.7	43	23	n.r.
Sarkar (2006) ⁵⁷	100%	n.r.	Abstract	India	2002–2004	n.r.	n.r.	20	8	n.r.
Uemura (2006) ⁵⁸	100%	n.r.	Abstract	Japan	2002–2003	n.r.	n.r.	10	3	n.r.
Dujic (2007) ⁵⁴	100%	5	Abstract	Serbia	n.r.	n.r.	n.r.	21	9	n.r.
Lin (2008) ⁷⁷	100%	5	Article	Taiwan	1995–2006	40.3	16.6	41	10	n.r.
Herpes zoster										
Dunic (2005) ⁵⁹	100%	n.r.	Article	Serbia	2000–2001	38.1	n.r.	115	14	n.r.
Kaposi's sarcoma										
Bower (2005) ¹⁷	100%	n.r.	Article	United Kingdom	1996–2004	37.9	n.r.	150	10	n.r.
De Schacht (2005) ⁶⁰	100%	n.r.	Abstract	Mozambique	2004	n.r.	n.r.	29	2	0
Progressive multifocal leucoencephalopathy										
Vidal (2008) ⁷⁸	100%	Other	Article	Brazil	2003–2004	37.3	45	12	1	0
Corral (2009) ⁷⁹	100%	Other	Abstract	Spain	1996–2008	n.r.	n.r.	53	12	n.r.
Any IRIS										
French (2000) ²²	5.3%	n.r.	Article	Australia	1996–1997	n.r.	n.r.	132	33	n.r.
Wnuk (2003) ³⁸	n.r.	n.r.	Abstract	Poland	n.r.	n.r.	n.r.	90	15	n.r.
Thomas (2004) ³⁶	43.5%	n.r.	Abstract	India	n.r.	n.r.	n.r.	23	6	n.r.

Author (Year)	Percent with AIDS at enrolment	Definition of IRIS *	Type of publication	Country	Study period	Mean age (years)	Median CD4 cell count (cells/ μ l)	No. of patients	No. developing IRIS	No. of deaths from IRIS
Jevtic (2005) ²³	3.2%	n.r.	Article	Serbia	1998–2004	41.0	108	389	65	1
Shelburne (2005) ³⁵	25.6%	2	Article	USA	1997–2003	38.8	n.r.	180	57	2
Bhrushundi (2006) ³¹	n.r.	n.r.	Abstract	India	n.r.	n.r.	n.r.	720	68	2
Chenghat (2006) ³²	n.r.	n.r.	Abstract	India	2004–2006	n.r.	n.r.	1342	42	n.r.
Ratnam (2006) ⁸⁰	2.5%	Other	Article	United Kingdom	2000–2002	35.0	174	199	44	n.r.
Rajasekaran (2006) ³³	n.r.	n.r.	Letter	India	2004–2005	n.r.	n.r.	2330	302	n.r.
Wijeyasangary (2006) ³⁷	n.r.	n.r.	Abstract	India	n.r.	n.r.	n.r.	200	7	2
Pulimood (2007) ²⁶	n.r.	Other	Abstract	India	2004–2006	n.r.	110.5	212	24	n.r.
Murdoch (2008) ⁸¹	n.r.	Other	Article	South Africa	2006	34	115	423	43	2
Sharma (2008) ⁸²	n.r.	Other	Letter	India	2004–2006	n.r.	n.r.	90	20	n.r.
Haddow (2009) ⁸³	68.9%	Other	Abstract	South Africa	2006–2007	35	106	498	116	5
Hoyo-Ulloa (2009) ⁸⁴	n.r.	n.r.	Abstract	Mexico	2001–2007	35	87	390	107	8
Khaykin (2009) ⁸⁵	43.6%	n.r.	Abstract	Germany	2001–2007	n.r.	n.r.	1014	181	n.r.
Poda (2009) ⁸⁶	n.r.	n.r.	Letter	Senegal	2003–2006	n.r.	n.r.	102	40	n.r.

n.r.; not reported

* See table 1 for definitions